Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide with and without tirzepatide in overweight or obesity
NCT06916065Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of eloralintide in obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve, Maximum Concentration and 2 more. Started Apr 2025; status: completed.
02
Drugs
eloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06916065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916065.